In a randomised treat-to-target trial, IDegAsp BID provided sustained glucose control before, during and after Ramadan fasting in patients with T2D previously treated with basal or premixed insulin ± OADs, with a significantly lower risk of hypoglycaemia than BIAsp 30 BID [62]. The gene discussed is INS; the disease is Hypoglycemia.